Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Relay Therapeutics, Inc.NASDAQ: RLAY
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 6.4% from a year ago
Cash & equivalents stood at $121.19M at the end of Q2 FY2026, up 6.4% from a year earlier and down 40.8% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.
Context
- Cash & equivalents amounted to 12.5% of total assets at the end of Q2 FY2026, down 3.1 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +6.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 84.02M USD
- Year-over-year change
- -32.4%
- 4-year CAGR
- -26.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.02M | -32.4% |
| FY2024 | 2024-12-31 | 124.29M | -13.5% |
| FY2023 | 2023-12-31 | 143.74M | -5.3% |
| FY2022 | 2022-12-31 | 151.79M | -45.8% |
| FY2021 | 2021-12-31 | 280.12M | — |
Cash & Equivalents vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's Jun 2026 cash & equivalents of $121.19M is the 5th highest of the 11 companies compared; the peer median is $102.9M.
- Its year-over-year change of +6.4% is the 8th highest of 11, against a peer median of +22.9%.
- Cash & equivalents amounts to 12.5% of total assets for RLAY, versus a peer median of 16.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $815.44M | +102.6% | +33.5% | 18.9% | |
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $157.52M | +21.2% | +18.0% | 15.3% | |
| Jun 2026 | $124.48M | -62.9% | +73.5% | 7.6% | |
| Jun 2026 | $121.19M | +6.4% | -17.9% | 12.5% | |
| Sep 2026 | $118.96M | +69.4% | -36.2% | 11.9% | |
| Sep 2026 | $86.84M | +48.8% | +23.3% | 8.4% | |
| Mar 2026 | $84.96M | -15.7% | -32.5% | 20.6% | |
| Mar 2026 | $62.1M | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $56.4M | +14.3% | -11.9% | 12.9% | |
| Mar 2026 | $21.76M | -46.0% | +4.8% | 18.2% | |
| Peer median (excluding RLAY) | $102.9M | +22.9% | +11.4% | 16.5% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 280.12M | 151.79M | 143.74M | 124.29M | 84.02M |
| Short-term Investments | 677.95M | 847.12M | 606.35M | 657.04M | 470.5M |
| Net Receivables | 4.94M | 5.22M | 0 | 0 | 0 |
| Inventory | 0 | 12.11M | 0 | 0 | 0 |
| Other Current Assets | 1.76M | 3.26M | 3.32M | 10.53M | 5.97M |
| Total Current Assets | 976.24M | 1.02B | 770.1M | 809.2M | 578.28M |
| Property, Plant & Equipment (Net) | 27.32M | 75.39M | 68.87M | 57.67M | 41.72M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.3M | 2.3M | 2.3M | 2.3M | 0 |
| Long-term Investments | 0 | 2.58M | 2.71M | 0 | 1.34M |
| Tax Assets | 0 | (2.58M) | 0 | 0 | 0 |
| Other Non-current Assets | 2.58M | 2.58M | 0 | 2.12M | 0 |
| Total Non-current Assets | 32.2M | 80.27M | 73.88M | 62.09M | 43.05M |
| Total Assets | 1.01B | 1.1B | 843.98M | 871.3M | 621.33M |
| Account Payables | 8.28M | 10.58M | 9.21M | 14.1M | 7.71M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 248K | 0 | 0 | 7.68M | 0 |
| Other Current Liabilities | 989K | 26.15M | 1.91M | 2.1M | 463K |
| Total Current Liabilities | 24.32M | 63.71M | 30.27M | 50.73M | 25.58M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 65.26M | 32.38M | 13.21M | 0 | 0 |
| Total Non-current Liabilities | 86.31M | 85.84M | 61.71M | 42.78M | 28.69M |
| Total Liabilities | 110.64M | 149.55M | 91.98M | 93.5M | 54.27M |
| Common Stock | 109K | 121K | 127K | 168K | 168K |
| Retained Earnings | (768.1M) | (1.06B) | (1.4B) | (1.74B) | (2.01B) |
| Accumulated OCI | (1.09M) | (10.42M) | (196K) | (991K) | 733K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 897.81M | 950.22M | 752M | 777.79M | 567.06M |
| Total Debt | 22.9M | 57.74M | 53.47M | 48.5M | 32.46M |
| Net Debt | (257.22M) | (94.05M) | (90.27M) | (75.79M) | (51.56M) |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.